News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Relypsa, Inc. Announces Presentation of Positive Phase 2 Results for RLY5016 at American Society of Hypertension Meeting


5/23/2011 7:15:37 AM

Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company’s lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels). These data were presented in a poster titled “A Multicenter, Open-Label, Single-Arm Study to Evaluate a Titration Regimen for the Potassium Binding Polymer RLY5016 in Patients with Heart Failure and Chronic Kidney Disease” (Poster PO-127) at the American Society of Hypertension Annual Meeting in New York.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES